Leonard Moise

NMR structural analysis of alpha-bungarotoxin and its complex with the principal alpha-neurotoxin-binding sequence on the alpha 7 subunit of a neuronal nicotinic acetylcholine receptor.

Putting immunoinformatics to the test.

Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine.

New tools, new approaches and new ideas for vaccine development.

Evolutionary deimmunization: an ancillary mechanism for self-tolerance?

Prediction of immunogenicity for therapeutic proteins: state of the art.

Analysis of ChimeriVax Japanese Encephalitis Virus envelope for T-cell epitopes and comparison to circulating strain sequences.

Vaccine renaissance--from basic research to implementation.

Progress towards a genome-derived, epitope-driven vaccine for latent TB infection.

Tularemia vaccines - an overview.

Identification of genome-derived vaccine candidates conserved between human and mouse-adapted strains of H. pylori.

Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes".

In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes.

Epitope-based vaccination against pneumonic tularemia.

Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccine.

K(V)4.2 channels tagged in the S1-S2 loop for alpha-bungarotoxin binding provide a new tool for studies of channel expression and localization.

A method for individualizing the prediction of immunogenicity of protein vaccines and biologic therapeutics: individualized T cell epitope measure (iTEM).

VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone.

HelicoVax: epitope-based therapeutic Helicobacter pylori vaccination in a mouse model.

H. pylori vaccines: why we still don't have any.

Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo.

Harnessing the power of genomics and immunoinformatics to produce improved vaccines.

Design and analysis of immune-evading enzymes for ADEPT therapy.

In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity.

Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine.

Of [Hamsters] and men: a new perspective on host cell proteins.

Moving Helicobacter pylori vaccine development forward with bioinformatics and immunomics.

The two-faced T cell epitope: examining the host-microbe interface with JanusMatrix.

Epitope recognition in HLA-DR3 transgenic mice immunized to TSH-R protein or peptides.

Building Better Biotherapeutics and Vaccines by Design: EpiVax, Inc., an Immunology Company.

Low immunogenicity predicted for emerging avian-origin H7N9: implication for influenza vaccine design.

Universal H1N1 influenza vaccine development: identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011.

Making vaccines "on demand": a potential solution for emerging pathogens and biodefense?

Immunization with cross-conserved H1N1 influenza CD4+ T-cell epitopes lowers viral burden in HLA DR3 transgenic mice.